The RNA targeted therapeutics market involves drugs that focus on modifying, silencing or enhancing RNA to treat various diseases. RNA therapeutics include techniques like antisense therapy, RNA interference and RNA-based gene therapy which can target and regulate the function of disease-associated RNAs and proteins. These therapies provide advantages like enhanced selectivity and efficacy over traditional small molecule drugs. Growing incidence of cancer, neurological disorders and genetic abnormalities have increased the demand for RNA targeted drugs globally.
The RNA targeted therapeutics market is estimated to be valued at USD 1.34 Bn in 2024 and is expected to reach USD 11.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 35.2% from 2024 to 2031.
Key players operating in the RNA targeted therapeutics are Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Sylentis and Quark Pharmaceuticals.
Growing demand: Increasing prevalence of cancer, neurodegenerative diseases and viral infections is driving the demand for RNA Targeted Therapeutics Market drugs globally. According to WHO, cancer burden is expected to grow by over 50% in the next 20 years.
Technological advancement: Emerging technologies like CRISPR are enabling more precise editing of RNA and facilitating development of novel therapeutics. Combination therapies targeting multiple RNA pathways also show promise.
Market Trends
Personalized medicine: RNA profiling and sequencing is allowing more personalized drug regimens based on individual patient's genetic makeup and disease characteristics. This improves efficacy and safety.
Partnerships and acquisitions: Pharma companies are partnering with biotechs and academic institutions to gain access to new targets and pipeline drugs. Recent acquisitions of biotechs by pharma giants will drive further research and commercialization.
Market Opportunities
Orphan drugs: Many RNA targeted therapies are being evaluated for rare genetic diseases with high unmet needs like spinal muscular atrophy. The orphan drug designation speeds up development and market approval.
Next-gen delivery: Novel delivery technologies like lipid nanoparticles, polymeric nanoparticles and exosomes are being explored to enhance stability and cellular uptake of RNA drugs, thereby improving clinical outcomes. This will expand the target disease areas.
Impact of COVID-19 on RNA Targeted Therapeutics Market Growth
The COVID-19 pandemic has significantly impacted the growth of the RNA targeted therapeutics market. In the initial months of the pandemic, most clinical trials related to RNA therapeutics were put on hold as healthcare resources were diverted towards tackling the health crisis. This led to delays in drug development programs and approvals. However, with COVID-19 directly impacting human RNA and gene expression, it also presented new opportunities for RNA targeted drugs and gene therapies to be repurposed or developed for treating the disease. Several biotech companies rapidly initiated clinical trials of existing RNA drugs to evaluate their efficacy against SARS-CoV-2 viral RNA.
With the pandemic expected to continue for the foreseeable future, it has accelerated the need as well as investments for developing effective RNA targeted drugs. Several virus-related vaccines in development are also based on nucleic acid platforms like DNA and mRNA. In the post-COVID era, the market is anticipated to witness robust growth. This is attributed to ongoing research on RNA drugs for COVID-19 along with continued clinical development and approvals for other non-COVID therapeutic areas like oncology and genetic disorders. The pandemic has showcased the immense potential of RNA drugs for treating infectious diseases, thereby enhancing their credibility amongst healthcare professionals and patients.
Geography-Wise Concentration of RNA Targeted Therapeutics Market
North America currently captures the largest share of the global RNA targeted therapeutics market, both in terms of value and volume. This is due to presence of major pharmaceutical companies and biotech firms engaged in RNA drug development in the US. Furthermore, higher healthcare spending along with faster regulatory approvals for novel biologics have supported market growth.
Europe holds the second largest market position. However, over the coming years, Asia Pacific is expected to emerge as the fastest growing regional market for RNA therapeutics. Rising incidence of chronic diseases, increasing disposable income, growing focus on developing indigenous biologics manufacturing capabilities are driving the Asia Pacific market. Presence of huge patient populations, especially in China and India makes it an attractive market for pharmaceutical companies globally.
Get more insights on - RNA Targeted Therapeutics Market
Get this Report in Japanese Language: RNA標的治療薬市場
Get this Report in Korean Language: RNA 표적 치료제 시장
Author Bio:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
